This article is more than 5 years old. Information may no longer be current.
Top checkpoint inhibitor stories from ACR 2016
Click Here to Manage Email Alerts
Healio Rheumatology features the top checkpoint inhibitor stories from the American College of Rheumatology Annual Meeting. More of Healio Rheumatology’s live coverage, including video interviews with researchers, can be found by clicking here.
Study: Joint, muscle pain common with the use of immune checkpoint inhibitors
WASHINGTON — Both joint and muscle pain commonly occurred in patients who received immune checkpoint inhibitors, according to a systematic review presented at the American College of Rheumatology Annual Meeting. Read More.
No immune-related adverse events found in 40% of patients who received immune checkpoint inhibitors
WASHINGTON — Despite most patients having an autoimmune disease at the time of checkpoint inhibition, no immune-related adverse events or disease exacerbation were found in 40% of patients who received immune checkpoint inhibitors, according to a systematic review of case reports presented at the American College of Rheumatology Annual Meeting. Read More.
Findings detail frequency of immune-related adverse events associated with pembrolizumab
WASHINGTON — Researchers found a higher adverse event rate than what was previously reported for patients who took pembrolizumab and noted a case of large-vessel vasculitis, according to an abstract presented at the American College of Rheumatology Annual Meeting. Read More.
Researchers evaluate immune-related adverse events
WASHINGTON — Researchers at the Cleveland Clinic have developed a system to evaluate and manage immune-related adverse events in patients with cancer treated with checkpoint inhibitors, according to an abstract presented at the American College of Rheumatology Annual Meeting. Read More.